Lexicon Pharmaceuticals, Inc. announced that the European Commission has approved Xermelo (telotristat ethyl) 250 mg as a first and only...
Lexicon Pharmaceuticals announced that the Committee for Medicinal Products for Human Use, the committee of the European Medicines Agency responsible...
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Lexicon Pharmaceuticals announced that the FDA has approved Xermelo (telotristat ethyl) 250 mg as a first and only orally administered...
The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs)...
Lexicon Pharmaceuticals announced that it has submitted a New Drug Application to the FDA seeking approval for the marketing and...
Lexicon Pharmaceuticals announced that the pivotal TELESTAR Phase III clinical trial of oral LX 1032 (telotristat etiprate) met its primary...
Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.